CV Date	20/07/2022

Part A. PERSONAL INFORMATION

First Name *	Javier		
Family Name *	Sánchez Céspedes		
Sex *	Male	Date of Birth *	05/01/1975
ID number Social Security, Passport *	34815046S	Phone Number *	636462616
URL Web	https://www.ibis-sevilla.es/investigacion/enfermedades-infecciosas-y-del-sistema-inmunitario/infecciones-viricas-y-en-pacientes-inmunodeprimidos/cordero-matia-elisa.aspx		
Email Address	jsanchez-ibis@us.es		
Researcher's identification number	Open Researcher and Contributor ID (ORCID) *	0000-0003-2707-1979	
	Researcher ID	B-1063-2014	
	Scopus Author ID	56628972200	

* Mandatory

A.1. Current position

Job Title	Researcher Nicolás Monardes (UCEIMP) / Investigador del Programa Nicolás Monardes (UCEIMP)		
Starting date	2019		
Institution	Andalusian Health Service / Servicio Andaluz de Salud		
Department / Centre	Infectious Diseases / University Hospital Virgen del Rocío / Instituto de Biomedicina de Sevilla		
Country	Spain	Phone Number	(34) 636462616
Keywords	Molecular mechanism of disease; Virus cultivation; Molecular, cellular and genetic biology; Clinical biology; Virology		

A.2. Previous positions

Period	Job Title / Name of Employer / Country
2016 - 2019	Postdoctoral Researcher / Investigador postdoctoral / University of Seville / Universidad de Sevilla
2015 - 2015	Postdoctoral Researcher / Investigador postdoctoral / University Hospital Virgen del Rocío (Hospital Universitario Virgen del Rocío) / Institute of Biomedicine of Seville (Instituto de Biomedicina de Sevilla
2010 - 2014	Postdoctoral Researcher "Sara Borrell" / Investigador postdoctoral "Sara Borrell" / University Hospital Virgen del Rocío (Hospital Universitario Virgen del Rocío) / Institute of Biomedicine of Seville (Instituto de Biomedicina de Sevilla) / Spain
2009 - 2012	Research Associate / Investigador postdoctoral / The Scripps Research Institute / United States of America
2001 - 2008	PhD student / Investigador predoctoral / Hospital Clínic of Barcelona / Hospital Clínico de Barcelona / Spain

A.3. Education

Degree/Master/PhD	University / Country	Year
Medicine / Medicina	University of Barcelona / Universidad de Barcelona / Spain	2008
Degree in Biology / Licenciado en Biología		2000

Degree/Master/PhD	University / Country	Year
	Autonomous University of Barcelona / Universidad Autónoma de Barcelona	

A.4. General quality indicators of scientific production

Total articles in publication list / Número total de artículos: 52
Total number of citations / Número total de citas:1029
Average citations per article / Número medio de citas por artículo: 21
h-index / índice-h: 17
Last updated / Última actualización: 15/06/2022
Source: Web of Science ResearcherID (B-1063-2014)

Part B. CV SUMMARY

Co-leader of the Viral Diseases and Infections in Immunodeficiencies Research Group at the Institute of Biomedicine of Seville (IBiS). Since August 2020 researcher with I3 certification by the Spanish General Secretariat of Universities and also certified by ANECA as Associate Professor. Principal investigator in 11 projects, 9 of them at national level, and participation in 14 other research projects funded in competitive calls. Member of the CIBER de Enfermedades Infecciosas (CIBERINFEC, CB21/13/00006), the Infectioous Diseases Spanish Network of Research in Infectious Pathology (REIPI RD16/0016/0009), the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), and the Spanish Society of Virology (SEIMC). Steering Committee of the COST Action CA19144: European Venom Network (EUVEN).

Regular participation in international collaborations, for example with the National Center for Advancing Translational Sciences, NCATS-NIH, USA (Dr. Juan Marugan), the University of Texas Medical Branch, USA (Prof. Jia. Zhou), the Sapienza Università di Roma, Italy (Prof. Bruno Botta), Saint Louis University, USA (Prof. Wold/Prof. Toth), and national, with the Plataforma Temática Interdisciplinar (PTI) Salud Global of CSIC, specifically in the identification and development of antivirals, with the Centro Nacional de Biotecnología (CNB, Dr. Carmen San Martín), the Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA, Dr. Juan Carlos Saiz), the University of Barcelona (Prof. Rodolfo Lavilla), or the Universidad Pompeu Fabra (UPF, Prof. Juana Díez).

Part C. RELEVANT ACCOMPLISHMENTS

C.1. Publications

AC: corresponding author. (nº x / nº y): position / total authors. If applicable, indicate the number of citations

1 **Scientific paper**. Molina-Ortega A; Martín-Gandul C; Mena-Romo JD; et al; Sanchez-Cespedes J; Cordero E. (8/10). 2018. Impact of pretransplant CMV-specific T-cell immune response in the control of CMV infection after solid organ transplantation: a prospective cohort study.Clinical Microbiology and Infection. WILEY-BLACKWEL. 0-0. ISSN 1198-743X. https://doi.org/10.1016/j.cmi.2018.09.019

2 **Scientific paper**. Marrugal Lorenzo JA; Serna-Gallego A; González-González L; et al; Sanchez-cespedes J (AC). (9/9). 2018. Inhibition of adenovirus infection by mifepristone Antiviral Research. ELSEVIER SCIENCE BV. 159, pp.77-83. ISSN 1872-9096. https://doi.org/10.1016/j.antiviral.2018.09.011

3 **Scientific paper**. Ghashghaei O; Caputo S; Sintes M; et al; Sánchez-céspedes J; Lavilla R. (13/17). 2018. Multiple Multicomponent Reactions: Unexplored Substrates, Selective Processes and Versatile Chemotypes in Biomedicine Chemistry - a European journal. WILEY-V C H VERLAG GMBH. ISSN 0947-6539. https://doi.org/10.1002/chem.201802877

4 **Scientific paper**. Pachón-Ibáñez, ME; Smani, Y; Pachón, J; Sanchez-Cespedes, J (AC). (4/4). 2017. Perspectives for clinical use of engineered human host defense antimicrobial peptides FEMS Microbiology Reviews. OXFORD UNIV PRESS. 41-3, pp.323-342. ISSN 0168-6445. https://doi.org/10.1093/femsre/fux012

5 **Scientific paper**. Sanchez-Cespedes J (AC); Martínez-Aguado P; Vega-Holm M; et al; Vega-Pérez JM. (1/9). 2016. New 4-Acyl-1-phenylaminocarbonyl-2-phenylpiperazine Derivatives as Potential Inhibitors of Adenovirus Infection. Synthesis, Biological Evaluation, and Structure-activity Relationships Journal of Medicinal Chemistry. American Chemical Society. 59-11, pp.5432-5448. ISSN 1520-4804. https://doi.org/10.1021/acs.jmedchem.6b00300

6 **Scientific paper**. von Reumont, BM; Anderluh, G; Antunes, A; et al; Sanchez-Cespedes J; Zancolli, G. (29/34). 2022. Modern venomics—Current insights, novel methods, and future perspectives in biological and applied animal venom research GigaScience. OXFORD UNIV PRESS. 11, pp.1-27.

7 **Scientific paper**. Cerrada-romero, cristina; Berastegui-Cabrera, Judith; Camacho-Martínez, P; et al; Sánchez-Céspedes, J (AC). (18/18). 2022. Excretion and viability of SARS-CoV-2 in feces and its association with the clinical outcome of COVID-19 Scientific Reports. NATURE RESEARCH. 12-1, pp.7397. https://doi.org/10.1038/s41598-022-11439-7

8 **Scientific paper**. 2021. Dendritic cell deficiencies persist seven months after SARS-CoV-2 infection Cellular & Molecular Immunology. https://doi.org/10.1038/s41423-021-00728-2

9 **Scientific paper**. Sanchez-Cespedes, J. (15/15). 2021. SARS-CoV-2 viral load in nasopharyngeal swabs is not an independent predictor of unfavorable outcome Scientific Reports. 11-1, pp.12931. ISSN 2045-2322. https://doi.org/10.1038/s41598-021-92400-y

10 **Scientific paper**. Sanchez-Cespedes, J. (10/10). 2021. Design, synthesis and in vitro biological evaluation of a novel class of anti-adenovirus agents based on 3-amino-1,2-propanediol Bioorganic Chemistry. 114. ISSN 0045-2068. https://doi.org/10.1016/j.bioorg.2021.105095

11 **Scientific paper**. Salto-Alejandre S; Jiménez-Jorge S; Sabé N; et al; Sanchez-Cespedes J; Cordero E. (27/28). 2021. Risk factors for unfavorable outcome and impact of early post-transplant infection in solid organ recipients with COVID-19: A prospective multicenter cohort study PloS One. PUBLIC LIBRARY SCIENCE. https://doi.org/10.1371/journal.pone.0250796

12 **Scientific paper**. Xu J; Berastegui-Cabrera J; Carretero-Ledesma M; et al; Sanchez-Cespedes J (AC). (9/9). 2021. Discovery of a Small Molecule Inhibitor of Human Adenovirus Capable of Preventing Escape from the Endosome International Journal of Molecular Sciences. MDPI. 22-4, pp.1617. ISSN 1422-0067. https://doi.org/10.3390/ijms22041617

13 **Scientific paper**. Sanchez-céspedes J (AC); Marrugal-Lorenzo JA; Martín-gandul C; et al; Aguilar-Guisado M. (1/12). 2021. T-cells immune response controls the high incidence of adenovirus infection in adult allogenic hematopoietic transplantation recipients Haematologica. Ferrata Storti Foundation. ISSN 1592-8721. https://doi.org/10.3324/haematol.2019.240101

14 **Scientific paper**. Berastegui-Cabrera J; Salto-Alejandre S; Valerio M; et al; Sanchez-cespedes J (AC). (24/24). 2020. SARS-CoV-2 RNAemia is associated with severe chronic underlying diseases but not with nasopharyngeal viral load Journal of Infection. S0163-20. https://doi.org/10.1016/j.jinf.2020.11.024

15 **Scientific paper**. Aydillo T; Escalera A; Strohmeier S; et al; Sanchez-Cespedes J; Cordero E. (5/16). 2020. Pre-existing Hemagglutinin Stalk Antibodies Correlate with Protection of Lower Respiratory Symptoms in Flu-Infected Transplant Patients Cell Reports Medicine. 1-8. https://doi.org/10.1016/j.xcrm.2020.100130

16 **Scientific paper**. Xu J; Berastegui-Cabrera J; Carretro-Ledesma M; Pachón-Díaz J; Chen H; Pachón-Ibáñez ME; Sanchez-Cespedes j; Zhou J (AC). (8/9). 2020. Discovery of Novel Substituted N-(4-Amino-2-chlorophenyl)-5-chloro-2-hydroxybenzamide Analogues as Potent Human Adenovirus Inhibitors Journal of Medicinal Chemistry. 63-21, pp.12830-12852. https://doi.org/10.1021/acs.jmedchem.0c01226

17 **Scientific paper**. Mazzota S; Berastegui-Cabrera J; Carullo G; et al; Sanchez-cespedes J (AC). (11/11). 2020. Serinol-Based Benzoic Acid Esters as New Scaffolds for the Development of Adenovirus Infection Inhibitors: Design, Synthesis, and In Vitro Biological Evaluation ACS Infectious Diseases. https://doi.org/10.1021/acsinfecdis.0c00515

18 **Scientific paper**. Pech-Puch D; Berastegui-Cabrera J; Pérez-Povedano M; et al; Sanchez-Cespedes J (AC). (12/12). 2020. Antiviral and antiproliferative potential of marine organisms from the Yucatan Peninsula, Mexico Frontiers Marine Science. FRONTIERS MEDIA SA. ISSN 2296-7745.

19 **Scientific paper**. Aguilar-Guisado M; Marrugal-Lorenzo JA; Berastegui-Cabrera J; Merino L; Pachón J (AC); Sanchez-Cespedes J. (5/5). 2020. In vitro co-infection by cytomegalovirus improves the antiviral activity of ganciclovir against human adenovirus International Journal of Antimicrobial Agents. https://doi.org/10.1016/j.ijantimicag.2020.106046

20 **Scientific paper**. Xu J; Berastegui-Cabrera J; Chen H; Pachón J; Zhou J; Sanchez-Cespedes J (AC). (6/6). 2020. Structure-Activity Relationship Studies on Diversified Salicylamide Derivatives as Potent Inhibitors of Human Adenovirus Infection Journal of Medicinal Chemistry. American Chemical Society. ISSN 1520-4804. https://doi.org/10.1021/acs.jmedchem.9b01950

21 **Scientific paper**. Mazzotta S; Marrugal-Lorenzo JA; Vega-Holm M; et al; Sánchez-Céspedes J (AC). (13/13). 2019. Optimization of piperazine-derived ureas privileged structures for effective antiadenovirus agents European Journal of Medicinal Chemistry. 185. ISSN 1768-3254. https://doi.org/10.1016/j.ejmech.2019.111840

22 **Scientific paper**. Marrugal-Lorenzo JA; Serna-Gallego A; Berastegui-Cabrera J; Pachón J; Sanchez-Cespedes J (AC). (5/5). 2019. Repositioning salicylanilide anthelmintic drugs to treat adenovirus infections Scientific Reports. Nature Publishing Group. ISSN 2045-2322. https://doi.org/10.1038/s41598-018-37290-3

23 **Scientific paper**. P. Martínez-Aguado; A. Serna-Gallego; J.A. Marrugal-Lorenzo; I. Gómez-Marín; J. Sanchez-Cespedes (AC). (5/5). 2015. Anti-adenovirus drug discovery: potential targets and evaluation methodologies Drug Discovery Today. ELSEVIER. 20-10, pp.1235-1242. ISSN 1359-6446. https://doi.org/10.1016/j.drudis.2015.07.007

24 **Scientific paper**. Sanchez Cespedes, J.; Moyer, CL.; Whitby, LR.; Boger, DL.; Nemerow, GR.2014. Inhibition of adenovirus replication by a trisubstituted piperazin-2-one derivative Antiviral Research. ELSEVIER SCIENCE BV. 108, pp.65-73. ISSN 1872-9096. https://doi.org/10.1016/j.antiviral.2014.05.010

25 **Scientific paper**. Reyes Andrade, J.; Sánchez Céspedes, J.; Olbrich, P.; Falcon, L.; Sanchez Ganfornina, I.; Tebruegge, M.; Pérez Romero, P.; Neth, O.2014. Meningoencephalitis due to adenovirus in a healthy infant mimicking severe bacterial sepsis Pediatric Infectious Disease Journal. LIPPINCOTT WILLIAMS & WILKINS. 33-4, pp.416-425. ISSN 1532-0987. https://doi.org/10.1097/INF.0000000000000128

C.3. Research projects and contracts

1 **Project**. DTS20/00010, Nuevos derivados salicilamida de niclosamida para su uso como agentes antivirales de amplio espectro. Instituto de Salud Carlos III. Javier Sánchez Céspedes. (Institute of biomedicie of Seville). 01/01/2021-31/12/2022. 106.150 €. Principal investigator.

2 **Project**. P18-RT-3320, Mecanismos inmunitarios implicados en el desarrollo y protección de neumonía gripal en adultos.. Consejería de Economía, Conocimiento, Empresas y Universidad. Junta de Andalucía. Javier Sánchez Céspedes. (Hospital Universitario Virgen del Rocío / Instituto de Biomedicina de Sevilla). 01/01/2020-31/12/2022. 119.652 €. Co-IP.

3 **Project**. PI18/01191, Estudio de la cinética de replicación e impacto clínico de la infección por adenovirus humano en pacientes con linfoma y leucemia linfoide crónica. Instituto de Salud Carlos III. Javier Sánchez Céspedes. (Hospital Universitario Virgen del Rocío/Instituto de Biomedicina de Sevilla). 01/01/2019-31/12/2021. 140.965 €. Team member.

4 **Project**. PI-0434-2018, Impacto de la respuesta inmunitaria en la incidencia de neumonía viral en pacientes hospitalizados con gripe estacional. Consejería de Salud de la Junta de Andalucía. (Hospital Universitario Virgen del Rocío/Instituto de Biomedicina de Sevilla). 01/01/2019-31/12/2021. 52.565,22 €. Team member.

5 **Project**. COV20/00580, Estudio de la carga viral de SARS-CoV-2 en vías respiratorias y sangre como factor asociado al pronóstico de la COVID-19 en adultos. Instituto de Salud Carlos III. Javier Sánchez Céspedes. (Institute of Biomedicine of Sevilla / Instituto de Biomedicina de Sevilla). 04/05/2020-04/05/2021. 189.765 €. Principal investigator.

6 **Project**. PI17/01055, Development and implementation of highly specific diagnosis criteria for the identification of the viral etiology in the community-acquired pneumonia. Proyectos de Investigación en Salud. Javier Sánchez Céspedes. (University Hospital Virgen del Rocío / Institute of Biomedicine of Seville). 01/01/2018-31/12/2020. 116.160 €. Principal investigator.

7 **Project**. DTS17/00130, New and innovative piperazine derivatives for the treatment of opportunistic viral infections. Instituto de Salud Carlos III. Javier Sánchez Céspedes. (Instituto de Biomedicina de Sevilla/Universidad de Sevilla). 02/01/2018-31/12/2019. 33.550 €. Principal investigator.

8 **Project**. Nuevos compuestos innovadores derivados de piperazina para el tratamiento de infecciones causadas por virus oportunistas. Universidad de Sevilla. Jerónimo Pachón Díaz. (Instituto de Biomedicina de Sevilla/Universidad de Sevilla). 18/05/2018-31/12/2018. 7.000 €. Team member.

9 **Project**. PI15/00489, Study of the incidence of adenovirus infection, its replication kinetics and the cellular immune response: impact in the clinical outcome of hematopoietic stem cell transplant recipients. Institute of Health Carlos III. Manuela Aguilar Guisado. (University Hospital Virgen del Rocío/Institute of Biomedicine of Seville). 01/01/2016-31/12/2018. 76.835 €. Team member.

10 **Project**. BIO2015-68990-REDT, Spanish Adenovirus Network: from basic biology to nanobiomedicine. Spanish Ministry of Economy and Competitiveness. Mª Carmen San Martín Pastrana. (University Hospital Virgen del Rocío / Institute of Biomedicine of Seville). 01/01/2016-01/01/2018. 31.000 €. Principal investigator.

11 **Project**. PI-0058-2012, New therapeutic approaches for the treatment of adenovirus infections in immunosuppressed patients: development of an animal model fo the evaluation of the efficacy and safety of anti-adenovirus small compounds generated by combinatorial chemistry (PI-0058-2012). Consejería de Salud y Bienestar Social. Junta de Andalucía. Javier Sánchez Céspedes. (University Hospital Virgen del Rocío / Institute of Biomedicine of Seville). 01/01/2013-31/12/2015. 51.300 €. Principal investigator.

12 **Project**. 3589-18, Nuevos compuestos innovadores derivados de piperazina para el tratamiento de infecciones causadas por virus oportunistas. Fundación para la Innovación y la Prospectiva en Salud en España (FIPSE). Javier Sánchez Céspedes. (Instituto de Biomedicina de Sevilla /Hospital Universitario Virgen del Rocío). From 01/06/2019. 25.000 €. Principal investigator.

C.4. Activities of technology / knowledge transfer and results exploitation

1 Judith Berastegui Cabrera; María Balsera Manzanero; Marta Carretero Ledesma; María Eugenia Pachón Ibáñez; Jerónimo Pachón Díaz; Elisa Cordero Matía; Javier Sánchez Céspedes. 2021/116. Microsomes: cellular-like structures to control viral infections (MICROTRAPS) Spain. 13/10/2021. Andalusian Health System/University of Seville.

2 Jia Zhou; Jimin Xu; Javier Sanchez Cespedes; Judith Berastegui Cabrera; María Eugenia Pachón Ibáñez; Jerónimo Pachó. PCT/US2021/015072. Salicylamide derivatives and related methods of making United States of America. 26/01/2021. University of Texas Medical Branch / Servicio Andaluz de Salud / Universidad de Sevilla.

3 Javier Sánchez Céspedes; Judith Berastegui Cabrera; Jerónimo Pachón Díaz; Jaime Rodríguez González; Carlos Jiménez González; Darwin Jesús Pech Puch. PCT/EP2020/071980. Furan, thiophene or gamma-lactam sesterterpene tetronic acids useful as antiviral compounds against infections caused by human adenovirus Spain. 07/08/2019. University of La Coruña/Andalusian Health System/University of Seville.

4 José Ignacio Candela Lena; Margarita Vega Holm; Fernando Iglesias Guerra; José Manuel Vega Pérez; Tania Cebreiro Cangueiro; Pablo Martínez Aguado; Jerónimo Pachón Díaz; María Eugenia Pachón Ibáñez; Javier Sánchez Céspedes. PCT/EP2017/054252. Piperazine derivatives as antiviral agents with increased therapeutic activity Spain. 23/02/2017. Andalusian Health System/University of Seville.